Patents by Inventor Yoshihiko Hirohashi

Yoshihiko Hirohashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190054141
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Application
    Filed: August 23, 2018
    Publication date: February 21, 2019
    Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Patent number: 10080776
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 25, 2018
    Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Publication number: 20180147270
    Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.
    Type: Application
    Filed: December 8, 2015
    Publication date: May 31, 2018
    Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Yoshihiko Hirohashi, Takayuki Kanaseki, Sho Miyamoto, Vitaly Kochin, Masashi Goto
  • Publication number: 20170360911
    Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.
    Type: Application
    Filed: December 8, 2015
    Publication date: December 21, 2017
    Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Yoshihiko Hirohashi, Takayuki Kanaseki, Sho Miyamoto, Vitaly Kochin, Masashi Goto
  • Publication number: 20170298109
    Abstract: The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 19, 2017
    Applicants: Sapporo Medical University, Medical & Biological Laboratories Co., Ltd.
    Inventors: Toshihiko Torigoe, Eri Atsuyama, Hironori Otaka, Kazue Nakano, Dongliang Li, Shingo Toji, Takuya Asano, Ryota Horibe, Yoshihiko Hirohashi, Noriyuki Sato, Tsuyoshi Saito
  • Publication number: 20160367628
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 22, 2016
    Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Publication number: 20160310583
    Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting cancer stem cells; a tumor antigen peptide specifically exhibited by cancer stem cells; a pharmaceutical composition for the prevention and/or treatment of cancer, containing same as an effective component thereof; and a method for screening said tumor antigen peptide. A peptide indicated by YO—XO—ZO, a polyepitope peptide including at least one said peptide as an epitope peptide and having a plurality of epitope peptides joined therein, a polynucleotide that codes at least either the peptide or the polyepitope peptide, a pharmaceutical composition containing these as an effective component thereof, and a cancer prevention and/or treatment agent characterized by inducing CTLs.
    Type: Application
    Filed: October 3, 2014
    Publication date: October 27, 2016
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., Sapporo Medical University
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Yoshihiko Hirohashi, Takayuki Kanaseki, Vitaly Kochin, Akari Takaya, Masashi Goto
  • Patent number: 9399760
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: July 26, 2016
    Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Publication number: 20160166666
    Abstract: Provided is a tumor antigen peptide and the like that is useful in the prevention and/or treatment of cancer. The present invention pertains to: a peptide comprising the amino acid sequence of sequence number 3, sequence number 4, sequence number 5, sequence number 6, or sequence number 11; a polyepitope peptide resulting from joining a plurality of epitope peptides and containing at least one of the aforementioned peptides as one epitope peptide; a polynucleotide coding for at least one of the polyepitope peptides or the peptides; a pharmaceutical composition containing the above as active ingredients; a cancer prevention and/or treatment agent characterized by inducing CTLs; and the like.
    Type: Application
    Filed: July 11, 2014
    Publication date: June 16, 2016
    Inventors: Keiki Masuda, Haruhisa Iguchi, Masashi Goto, Toshihiko Torigoe, Yoshihiko Hirohashi, Rena Morita
  • Publication number: 20140044686
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 13, 2014
    Applicants: Dainippon Sumitomo Pharma Co., Ltd., Sapporo Medical University
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Patent number: 8541544
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: September 24, 2013
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Sapporo Medical University
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Publication number: 20110262358
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Application
    Filed: October 27, 2009
    Publication date: October 27, 2011
    Applicants: Sapporo Medical University, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Publication number: 20100034780
    Abstract: The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like.
    Type: Application
    Filed: June 27, 2006
    Publication date: February 11, 2010
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Ichiya Honma, Yoshihiko Hirohashi, Kenji Harada
  • Publication number: 20100015101
    Abstract: The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 27, 2007
    Publication date: January 21, 2010
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Yoshihiko Hirohashi, Kenji Harada
  • Patent number: 7601801
    Abstract: The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.
    Type: Grant
    Filed: July 7, 2004
    Date of Patent: October 13, 2009
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Hiroyuki Hariu, Yoshihiko Hirohashi
  • Publication number: 20070036812
    Abstract: The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.
    Type: Application
    Filed: July 7, 2004
    Publication date: February 15, 2007
    Inventors: Noriyuki Sato, Toshihiki Torigoe, Hiroyuki Hariu, Yoshihiko Hirohashi